🔴 Safety Alert
The U.S. Food and Drug Administration (FDA) has issued an early alert regarding Becton Dickinson (BD) Intraosseous Vascular Access System Needle Sets, warning of potential difficulty in removing the obturator (stylet) following catheter placement. The alert signals a device malfunction that could delay emergency vascular access in critical clinical situations.
Key takeaways
- BD Intraosseous Vascular Access System Needle Sets carry a risk of obturator removal difficulty after placement
- The FDA early alert mechanism notifies clinicians before a formal recall is issued
- Affected devices are used for emergency intravenous access in patients requiring rapid fluid or medication administration
- Healthcare facilities should verify inventory and follow FDA guidance on device handling pending further updates
What the alert covers
The FDA early alert on the BD Intraosseous issue specifies difficulty or failure in removing the obturator—the solid stylet that prevents blood backflow during needle insertion. Once the needle is placed into the bone marrow cavity, clinicians must remove the obturator to allow fluid or medication infusion. If removal becomes difficult or impossible, the device cannot function as intended.
Intraosseous (IO) access is a critical emergency procedure, particularly in trauma, pediatric resuscitation, and shock scenarios where peripheral venous access is unavailable or has failed. Any malfunction in IO needle systems poses direct patient safety risk through delayed access to life-saving fluids and medications.
Clinical context and affected populations
The BD Intraosseous Vascular Access System is used in emergency departments, trauma centers, intensive care units, and pre-hospital settings across North America. The system is designed for rapid placement in conscious and unconscious patients, including infants and children. Obturator removal difficulty could affect clinical workflows during time-critical resuscitation scenarios.
Healthcare facilities using BD IO needle sets should check inventory immediately and report any instances of obturator removal difficulty to the FDA’s Medical Device Reporting (MDR) system. Clinicians experiencing resistance during obturator removal should not force the component, as this may damage the device or injure surrounding tissue.
Regulatory pathway forward
An early alert differs from a formal recall in that it provides urgent notification to healthcare providers before the FDA has completed its investigation and classification of the defect. BD and the FDA are investigating the scope, root cause, and frequency of the obturator removal issue. A formal recall or additional guidance is expected as the investigation concludes.
Healthcare facilities should maintain current contact with their device suppliers and monitor the FDA’s official recalls and alerts webpage for updates. Any adverse events or near-misses involving BD IO needle sets should be reported through the MDR system to support the ongoing investigation.
The FDA has alerted healthcare providers to potential difficulty removing the obturator from BD Intraosseous Vascular Access System Needle Sets, a complication that could delay emergency vascular access in critically ill or injured patients.
— U.S. Food and Drug Administration, Medical Device Alert (2024)
What this means
Frequently asked questions
What is an intraosseous needle and when is it used?
An intraosseous (IO) needle allows rapid access to the bone marrow cavity for fluid, blood, or medication administration when peripheral veins cannot be quickly accessed. IO access is used in cardiac arrest, severe trauma, burns, sepsis, and pediatric emergencies where minutes matter. The procedure is minimally invasive and approved for both pre-hospital and in-hospital use.
What should I do if I encounter obturator removal difficulty?
Do not force or twist the obturator, as this may break the device or injure the patient. Notify your clinical supervisor, document the incident in detail, and report it to the FDA via the Medical Device Reporting (MDR) system through your hospital’s biomedical or device safety department. This information helps the FDA determine the scope of the problem.
Should hospitals stop using BD IO needle sets immediately?
The FDA has not issued a formal recall or use suspension. Hospitals should continue using affected devices while following proper technique and monitoring for issues. However, facilities may consider stocking alternative IO products from other manufacturers as a precaution. Contact your hospital’s pharmacy and biomedical departments for guidance specific to your institution.
As the FDA investigation progresses, additional information on the root cause, affected lot numbers, and recommended actions will be released. Healthcare providers are encouraged to subscribe to FDA Safety Alerts to receive timely updates on this and similar device safety issues affecting emergency care systems.
Source: FDA Early Alert: Intraosseous Needle Set Issue – Becton Dickinson
Was this article helpful?
Related Coverage
